RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Over 80% of uveal melanomas (UMs) feature GNAQ or GNA11 mutations, leading to constitutive Gαq signaling and MAPK activation.
• Protein kinase C (PKC) is implicated in this pathway, but the precise mechanisms linking Gαq activation to MAPK remain incompletely understood.

Purpose of the Study:

• To elucidate the mechanistic details of MAPK activation downstream of oncogenic GNAQ/11 mutations in uveal melanoma.
• To identify key molecular players and signaling events connecting Gαq activation to MAPK pathway stimulation.

Main Methods:

• Investigated the roles of specific PKC isoforms (PKCδ and PKCɛ) in MAPK activation in GNAQ-mutant melanoma cells.
• Quantified RasGRP3 expression levels in response to GNAQ/11 mutations.
• Examined the mechanisms of RasGRP3 activation, including phosphorylation and membrane recruitment.

Main Results:

• PKCδ and PKCɛ were identified as essential and sufficient for MAPK activation in GNAQ-mutant melanomas.
• RasGRP3 was found to be significantly and selectively overexpressed in UM due to GNAQ/11 mutations.
• RasGRP3 activation involves both PKCδ/ɛ-dependent phosphorylation and diacylglycerol (DAG)-mediated membrane recruitment, independent of PKC activity.

Conclusions:

• RasGRP3 is a critical mediator of MAPK activation downstream of GNAQ/11 mutations in uveal melanoma.
• The dual activation mechanism of RasGRP3 (phosphorylation and membrane recruitment) may explain the limited efficacy of PKC inhibitors.
• RasGRP3 represents a promising therapeutic target for uveal melanomas driven by oncogenic GNAQ/11 mutations.